A Phase 2 interventional study of Afabicin and Cefazolin in Bone or Joint Infection, sponsored by Debiopharm International SA. Terminated at 19 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, active-controlled, open-label study to assess the safety, tolerability and efficacy of Afabicin in the treatment of participants with bone or joint infection due to Staphylococcus aureus [both methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)] and/or coagulase-negative staphylococci (CoNS) and to compare it to standard of care (SoC).
Debiopharm International SA is the lead sponsor of 51 studies on the registry; 6 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
For patients with DFO:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received afabicin intravenously (IV) at a dose of 160 milligrams (mg), twice daily (BID), followed by a switch to oral afabicin at a dose of 240 mg, BID, for 2-3 weeks.
Drug: Afabicin
Participants received afabicin IV at a dose of 160 mg, BID, followed by a switch to oral afabicin at a dose of 240 mg, BID, for 3-6 weeks.
Drug: Afabicin
Participants with oxacillin-/methicillin-susceptible staphylococci were administered with either cefazolin or vancomycin or linezolid or clindamycin, IV or linezolid or clindamycin, orally; participants with oxacillin-/methicillin-resistant staphylococci were administered either vancomycin or clindamycin or linezolid, IV or linezolid or clindamycin, orally, as part of SoC in accordance with local practice and applicable treatment guidelines without exceeding the maximum dosing schedule.
Drug: Cefazolin · Drug: Vancomycin · Drug: Linezolid · Drug: Clindamycin
Participants with oxacillin-/methicillin-susceptible staphylococci were administered with either cefazolin or vancomycin or linezolid or clindamycin, IV or linezolid or clindamycin, orally; participants with oxacillin-/methicillin-resistant staphylococci were administered either vancomycin or clindamycin or linezolid, IV or linezolid or clindamycin, orally, as part of SoC in accordance with local practice and applicable treatment guidelines without exceeding the maximum dosing schedule.
Drug: Cefazolin · Drug: Vancomycin · Drug: Linezolid · Drug: Clindamycin
Participants received afabicin IV at a dose of 55 mg, BID, followed by a switch to oral afabicin at a dose of 80 mg, BID, for 2-3 weeks.
Drug: Afabicin
Participants received afabicin IV at a dose of 55 mg, BID, followed by a switch to oral afabicin at a dose of 80 mg, BID, for 3-6 weeks.
Drug: Afabicin
Participants with oxacillin-/methicillin-susceptible staphylococci were administered with either cefazolin or vancomycin or linezolid or clindamycin, IV or linezolid or clindamycin, orally; participants with oxacillin-/methicillin-resistant staphylococci were administered either vancomycin or clindamycin or linezolid, IV or linezolid or clindamycin, orally, as part of SoC in accordance with local practice and applicable treatment guidelines without exceeding the maximum dosing schedule.
Drug: Cefazolin · Drug: Vancomycin · Drug: Linezolid · Drug: Clindamycin
Participants with oxacillin-/methicillin-susceptible staphylococci were administered with either cefazolin or vancomycin or linezolid or clindamycin, IV or linezolid or clindamycin, orally; participants with oxacillin-/methicillin-resistant staphylococci were administered either vancomycin or clindamycin or linezolid, IV or linezolid or clindamycin, orally, as part of SoC in accordance with local practice and applicable treatment guidelines without exceeding the maximum dosing schedule.
Drug: Cefazolin · Drug: Vancomycin · Drug: Linezolid · Drug: Clindamycin
Administered intravenously and orally.
Administered intravenously.
Administered intravenously.
Administered intravenously and orally.
Administered intravenously and orally.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. TEAE is any undesirable event either not present prior to medical treatment or worsening (in intensity or frequency) following treatment. SAE is defined as any untoward medical occurrence that at any dose: results in death; is life-threatening (i.e., puts the patient at immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect, or is otherwise medically significant.
Time frame: Up to Day 142
Number of Participants With Grade Shift From Baseline in Hematology Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 4.03
Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.
Time frame: Up to Day 142
Number of Participants With Grade Shift From Baseline in Clinical Chemistry Parameters Based on NCI-CTCAE v4.03
Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.
Time frame: Up to Day 142
Number of Participants With Grade Shift From Baseline in Electrolyte Parameters Based on NCI-CTCAE v4.03
Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.
Time frame: Up to Day 142
Number of Participants With Grade Shift From Baseline in Coagulation Parameters Based on NCI-CTCAE v4.03
Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.
Time frame: Up to Day 142
Number of Participants With Post-baseline Clinically Significant Urinalysis Abnormalities
Clinical significance of abnormalities in urinalysis was determined based on the investigator's discretion. Baseline is defined as the last assessment prior to the randomization.
Time frame: Up to Day 142
Percentage of Participants With Clinical Response
Clinical response was based on the improvement of disease-specific signs and symptoms. Responders are defined as participants meeting all the following criteria: improvement of disease-specific signs and symptoms and no new signs, symptoms or complications attributable to the initial infection; No evidence of drainage, sinus tract formation or infection-related bone instability; No requirement for subsequent antibiotics with activity against Staphylococcus to treat the initial infection after the start of study treatment; Microbiological eradication of the baseline pathogen (if post-baseline sample\[s\] are available); Imaging test at 12 weeks post-EOT showing no worsening of baseline pathology or presence of signs indicating resolution or healing of the infection. Percentages are rounded off.
Time frame: Part A: At Day 8, EOT (up to Day 22), 4-weeks post-EOT (up to Day 50), and 12-weeks post-EOT (up to Day 130); Part B: At Day 8, Day 28, Day 42, EOT (up to Day 43), 4-weeks post-EOT (up to Day 73), and 12-weeks post-EOT (up to Day 142)
Participants took part in the study at various investigative sites from 20 February 2019 to 23 April 2025.
| Milestone | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Started | 8 | 5 | 3 | 1 | 18 | 24 | 4 | 4 |
| Completed | 8 | 5 | 3 | 1 | 14 | 19 | 3 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 4 | 5 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal of consent | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Withdrew: Participant unable to come to visit | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Participant withdrawn due to streptococcus report after randomization | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Screen failure | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. TEAE is any undesirable event either not present prior to medical treatment or worsening (in intensity or frequency) following treatment. SAE is defined as any untoward medical occurrence that at any dose: results in death; is life-threatening (i.e., puts the patient at immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect, or is otherwise medically significant.
| Participants | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| TEAEs | 3 | 3 | 0 | 0 | 10 | 17 | 2 | 3 |
| SAEs | 0 | 1 | 0 | 0 | 3 | 4 | 1 | 0 |
Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.
| Participants | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Haemoglobin (High): Grade 0 (normal) to Grade 0 (normal) | 7 | 5 | 3 | 1 | 18 | 22 | 4 | 2 |
| Haemoglobin(High): Grade 0 (normal) to Grade 1 (high) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Haemoglobin (Low): Grade 0 (normal) to Grade 0 (normal) | 4 | 1 | 2 | 0 | 9 | 2 | 3 | 3 |
| Haemoglobin (Low): Grade 0 (normal) to Grade 1 (low) | 2 | 1 | 0 | 0 | 5 | 5 | 0 | 0 |
| Haemoglobin (Low): Grade 0 (normal) to Grade 2 (low) | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 |
| Haemoglobin (Low): Grade 1 (low) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Haemoglobin (Low): Grade 1 (low) to Grade 1 (low) | 2 | 2 | 1 | 0 | 1 | 5 | 0 | 0 |
| Haemoglobin (Low): Grade 1 (low) to Grade 2 (low) | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Haemoglobin (Low): Grade 2 (low) to Grade 1 (low) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Haemoglobin (Low): Grade 2 (low) to Grade 2 (low) | 0 | 1 | 0 | 0 | 1 | 4 | 0 | 0 |
| Haemoglobin (Low): Grade 2 (low) to Grade 3 (low) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Haemoglobin (Low): Grade 3 (low) to Grade 3 (low) | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Leukocytes (High): Grade 0 (normal) to Grade 0 (normal) | 8 | 5 | 3 | 1 | 18 | 22 | 4 | 4 |
| Leukocytes (Low): Grade 0 (normal) to Grade 0 (normal) | 7 | 4 | 3 | 1 | 15 | 19 | 4 | 4 |
| Leukocytes (Low): Grade 0 (normal) to Grade 1 (low) | 1 | 1 | 0 | 0 | 2 | 3 | 0 | 0 |
| Leukocytes (Low): Grade 1 (low) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Lymphocytes (High): Grade 0 (normal) to Grade 0 (normal) | 8 | 5 | 3 | 0 | 18 | 21 | 4 | 4 |
| Lymphocytes (High): Grade 0 (normal) to Grade 2 (high) | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Lymphocytes (Low): Grade 0 (normal) to Grade 0 (normal) | 5 | 5 | 1 | 1 | 12 | 14 | 4 | 3 |
| Lymphocytes (Low): Grade 0 (normal) to Grade 1 (low) | 2 | 0 | 2 | 0 | 2 | 1 | 0 | 0 |
| Lymphocytes (Low): Grade 0 (normal) to Grade 2 (low) | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 |
| Lymphocytes (Low): Grade 1 (low) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Lymphocytes (Low): Grade 1 (low) to Grade 1 (low) | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Lymphocytes (Low): Grade 2 (low) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Lymphocytes (Low): Grade 2 (low) to Grade 1 (low) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Lymphocytes (Low): Grade 3 (low) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Neutrophils (Low): Grade 0 (normal) to Grade 0 (normal) | 7 | 4 | 3 | 1 | 16 | 18 | 4 | 3 |
| Neutrophils (Low): Grade 0 (normal) to Grade 1 (low) | 1 | 0 | 0 | 0 | 1 | 3 | 0 | 0 |
| Neutrophils (Low): Grade 0 (normal) to Grade 2 (low) | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| Neutrophils (Low): Grade 0 (normal) to Grade 3 (low) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Platelets (Low): Grade 0 (normal) to Grade 0 (normal) | 8 | 5 | 3 | 1 | 17 | 19 | 3 | 3 |
| Platelets (Low): Grade 0 (normal) to Grade 1 (low) | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 1 |
Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.
| Participants | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Alanine Aminotransferase (High): Grade 0 (normal) to Grade 0 (normal) | 4 | 3 | 3 | 1 | 8 | 11 | 2 | 1 |
| Alanine Aminotransferase (High): Grade 0 (normal) to Grade 1 (high) | 1 | 1 | 0 | 0 | 8 | 8 | 2 | 1 |
| Alanine Aminotransferase (High): Grade 0 (normal) to Grade 2 (high) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Alanine Aminotransferase (High): Grade 0 (normal) to Grade 4 (high) | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Alanine Aminotransferase (High): Grade 1 (high) to Grade 1 (high) | 3 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Alanine Aminotransferase (High): Grade 1 (high) to Grade 2 (high) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Alkaline Phosphatase (High): Grade 0 (normal) to Grade 0 (normal) | 6 | 1 | 3 | 0 | 10 | 10 | 3 | 2 |
| Alkaline Phosphatase (High): Grade 0 (normal) to Grade 1 (high) | 0 | 2 | 0 | 1 | 7 | 8 | 0 | 1 |
| Alkaline Phosphatase (High): Grade 0 (normal) to Grade 2 (high) | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Alkaline Phosphatase (High): Grade 1 (high) to Grade 0 (normal) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline Phosphatase (High): Grade 1 (high) to Grade 1 (high) | 1 | 1 | 0 | 0 | 1 | 3 | 1 | 1 |
| Aspartate Aminotransferase (High): Grade 0 (normal) to Grade 0 (normal) | 7 | 2 | 3 | 1 | 12 | 14 | 3 | 2 |
| Aspartate Aminotransferase (High): Grade 0 (normal) to Grade 1 (high) | 0 | 2 | 0 | 0 | 5 | 5 | 1 | 1 |
| Aspartate Aminotransferase (High): Grade 0 (normal) to Grade 2 (high) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Aspartate Aminotransferase (High): Grade 0 (normal) to Grade 4 (high) | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Aspartate Aminotransferase (High): Grade 1 (high) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Aspartate Aminotransferase (High): Grade 1 (high) to Grade 1 (high) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Aspartate Aminotransferase (High): Grade 1 (high) to Grade 2 (high) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin (High): Grade 0 (normal) to Grade 0 (normal) | 8 | 4 | 3 | 1 | 14 | 20 | 3 | 3 |
| Bilirubin (High): Grade 0 (normal) to Grade 1 (high) | 0 | 1 | 0 | 0 | 2 | 2 | 1 | 1 |
| Bilirubin (High): Grade 0 (normal) to Grade 2 (high) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Bilirubin (High): Grade 0 (normal) to Grade 3 (high) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Creatine Kinase (High): Grade 0 (normal) to Grade 0 (normal) | 5 | 1 | 3 | 1 | 9 | 5 | 4 | 2 |
| Creatine Kinase (High): Grade 0 (normal) to Grade 1 (high) | 2 | 3 | 0 | 0 | 7 | 10 | 0 | 1 |
| Creatine Kinase (High): Grade 0 (normal) to Grade 2 (high) | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Creatine Kinase (High): Grade 0 (normal) to Grade 3 (high) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Creatine Kinase (High): Grade 1 (high) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Creatine Kinase (High): Grade 1 (high) to Grade 1 (high) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Creatine Kinase (High): Grade 1 (high) to Grade 2 (high) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Creatine Kinase (High): Grade 1 (high) to Grade 3 (high) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Creatine Kinase (High): Grade 2 (high) to Grade 1 (high) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Creatine Kinase (High): Grade 2 (high) to Grade 2 (high) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Creatine Kinase: Missing to Missing | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine (High): Grade 0 (normal) to Grade 0 (normal) | 7 | 5 | 3 | 1 | 15 | 16 | 4 | 4 |
| Creatinine (High): Grade 0 (normal) to Grade 1 (high) | 1 | 0 | 0 | 0 | 2 | 3 | 0 | 0 |
| Creatinine (High): Grade 1 (high) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Creatinine (High): Grade 1 (high) to Grade 2 (high) | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Gamma Glutamyl Transferase (High): Grade 0 (normal) to Grade 0 (normal) | 5 | 2 | 3 | 1 | 13 | 13 | 3 | 2 |
| Gamma Glutamyl Transferase (High): Grade 0 (normal) to Grade 1 (high) | 1 | 0 | 0 | 0 | 1 | 3 | 1 | 1 |
| Gamma Glutamyl Transferase (High): Grade 0 (normal) to Grade 2 (high) | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 |
| Gamma Glutamyl Transferase (High): Grade 0 (normal) to Grade 4 (high) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gamma Glutamyl Transferase (High): Grade 1 (high) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Gamma Glutamyl Transferase (High): Grade 1 (high) to Grade 1 (high) | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Gamma Glutamyl Transferase (High): Grade 1 (high) to Grade 2 (high) | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Gamma Glutamyl Transferase (High): Grade 2 (high) to Grade 2 (high) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Gamma Glutamyl Transferase (High): Grade 2 (high) to Grade 3 (high) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Gamma Glutamyl Transferase (High): Grade 3 (high) to Grade 3 (high) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Glomerular Filtration Rate (Low): Grade 0 (normal) to Grade 0 (normal) | 6 | 2 | 2 | 1 | 8 | 9 | 2 | 2 |
| Glomerular Filtration Rate (Low): Grade 0 (normal) to Grade 1 (low) | 2 | 2 | 0 | 0 | 7 | 2 | 0 | 1 |
| Glomerular Filtration Rate (Low): Grade 0 (normal) to Grade 2 (low) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Glomerular Filtration Rate (Low): Grade 1 (low) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Glomerular Filtration Rate (Low): Grade 1 (low) to Grade 1 (low) | 0 | 1 | 1 | 0 | 2 | 5 | 1 | 1 |
| Glomerular Filtration Rate (Low): Grade 1 (low) to Grade 2 (low) | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Glomerular Filtration Rate (Low): Grade 2 (low) to Grade 1 (low) | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Glomerular Filtration Rate (Low): Grade 2 (low) to Grade 2 (low) | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Glucose (High): Grade 0 (normal) to Grade 0 (normal) | 4 | 3 | 3 | 0 | 17 | 6 | 3 | 1 |
| Glucose (High): Grade 0 (normal) to Grade 1 (high) | 3 | 1 | 0 | 1 | 2 | 8 | 0 | 2 |
| Glucose (High): Grade 0 (normal) to Grade 3 (high) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Glucose (High): Grade 1 (high) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Glucose (High): Grade 1 (high) to Grade 1 (high) | 1 | 1 | 0 | 0 | 2 | 2 | 0 | 1 |
| Glucose (High): Grade 1 (high) to Grade 2 (high) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Glucose (High): Grade 2 (high) to Grade 1 (high) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Glucose (High): Grade 2 (high) to Grade 2 (high) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Glucose (High): Grade 3 (high) to Grade 1 (high) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Glucose (High): Grade 3 (high) to Grade 3 (high) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Glucose (Low): Grade 0 (normal) to Grade 0 (normal) | 8 | 4 | 2 | 1 | 16 | 18 | 4 | 4 |
| Glucose (Low): Grade 0 (normal) to Grade 1 (low) | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 0 |
| Glucose (Low): Grade 1 (low) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Glucose (Low): Grade 1 (low) to Grade 1 (low) | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Urate (High): Grade 0 (normal) to Grade 0 (normal) | 8 | 5 | 3 | 1 | 12 | 16 | 4 | 1 |
| Urate (High): Grade 0 (normal) to Grade 1 (high) | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 2 |
| Urate (High): Grade 1 (high) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Urate (High): Grade 1 (high) to Grade 1 (high) | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 |
| Urate (High): Grade 4 (high) to Grade 4 (high) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.
| Participants | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Magnesium (High): Grade 0 (normal) to Grade 0 (normal) | 7 | 4 | 2 | 1 | 13 | 22 | 4 | 4 |
| Magnesium (High): Grade 0 (normal) to Grade 1 (high) | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 0 |
| Magnesium (High): Grade 0 (normal) to Grade 3 (high) | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Magnesium (High): Missing to Grade 0 (normal) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Magnesium (High): Grade 1 (high) to Grade 1 (high) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Magnesium (Low): Grade 0 (normal) to Grade 0 (normal) | 6 | 5 | 3 | 1 | 6 | 17 | 4 | 3 |
| Magnesium (Low): Grade 0 (normal) to Grade 1 (low) | 2 | 0 | 0 | 0 | 7 | 3 | 0 | 1 |
| Magnesium (Low): Grade 0 (normal) to Grade 2 (low) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Magnesium (Low): Grade 0 (normal) to Grade 3 (low) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Magnesium (Low): Missing to Grade 0 (normal) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Magnesium (Low): Grade 1 (low) to Grade 1 (low) | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Magnesium (Low): Grade 3 (low) to Grade 3 (low) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Magnesium (Low): Grade 3 (low) to Grade 4 (low) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Potassium (High): Grade 0 (normal) to Grade 0 (normal) | 7 | 3 | 2 | 1 | 8 | 11 | 2 | 4 |
| Potassium (High): Grade 0 (normal) to Grade 1 (high) | 0 | 1 | 0 | 0 | 1 | 3 | 2 | 0 |
| Potassium (High): Grade 0 (normal) to Grade 2 (high) | 0 | 1 | 1 | 0 | 4 | 5 | 0 | 0 |
| Potassium (High): Grade 0 (normal) to Grade 3 (high) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Potassium (High): Grade 1 (high) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 |
| Potassium (High): Grade 1 (high) to Grade 1 (high) | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Potassium (High): Grade 2 (high) to Grade 0 (normal) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium (Low): Grade 0 (normal) to Grade 0 (normal) | 8 | 5 | 3 | 1 | 15 | 17 | 2 | 2 |
| Potassium (Low): Grade 0 (normal) to Grade 1 (low) | 0 | 0 | 0 | 0 | 3 | 4 | 1 | 2 |
| Potassium (Low): Grade 1 (low) to Grade 3 (low) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Potassium (Low): Grade 1 (low) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Sodium (High): Grade 0 (normal) to Grade 0 (normal) | 8 | 4 | 3 | 1 | 10 | 22 | 3 | 2 |
| Sodium (High): Grade 0 (normal) to Grade 1 (high) | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 1 |
| Sodium (High): Grade 0 (normal) to Grade 2 (high) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Sodium (High): Grade 0 (normal) to Grade 4 (high) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium (High): Missing to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Sodium (High): Grade 1 (high) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Sodium (High): Grade 1 (high) to Grade 1 (high) | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Sodium (High): Grade 1(high) to Grade 3 (high) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Sodium (Low): Grade 0 (normal) to Grade 0 (normal) | 8 | 4 | 3 | 1 | 11 | 19 | 2 | 3 |
| Sodium (Low): Grade 0 (normal) to Grade 1 (low) | 0 | 1 | 0 | 0 | 5 | 2 | 2 | 0 |
| Sodium (Low): Grade 0 (normal) to Grade 3 (low) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Sodium (Low): Missing to Grade 0 (normal) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Sodium (Low): Grade 1 (low) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Calcium, Ionized (High): Grade 0 (normal) to Grade 0 (normal) | — | — | — | — | — | 16 | — | 2 |
| Calcium, Ionized (High): Grade 0 (normal) to Grade 1(high) | — | — | — | — | — | 1 | — | 0 |
| Calcium, Ionized (High): Missing to Grade 0 (normal) | — | — | — | — | — | 1 | — | 0 |
| Calcium, Ionized (Low): Grade 0 (normal) to Grade 0 (normal) | — | — | — | — | — | 15 | — | 2 |
| Calcium, Ionized (Low): Grade 1 (low) to Grade 0 (normal) | — | — | — | — | — | 1 | — | 0 |
| Calcium, Ionized (Low): Grade 1 (low) to Grade 2 (low) | — | — | — | — | — | 1 | — | 0 |
| Calcium, Ionized (Low): Missing to Grade 1 (low) | — | — | — | — | — | 1 | — | 0 |
Laboratory abnormalities were graded according to NCI CTCAE v4.03. Grade 0 indicates a normal value; Grades 1-4 represent increasing severity of abnormalities outside the normal range. "High" and "Low" indicate values above and below the normal range, respectively. At baseline (last assessment prior to randomization), both "High, Grade 0" and "Low, Grade 0" indicate normal values and identify the direction of the subsequent post-baseline shift. Participants were evaluated separately for High and Low shifts. Participant could contribute to both analyses if shifts occurred in opposite directions at different assessments. These categories are not mutually exclusive; therefore, counts should not be summed across directions, as they may exceed the number of participants analyzed. Participant could not be classified as both High and Low at the same assessment. Only categories with at least one participant showing a shift were reported.
| Participants | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Activated Partial Thromboplastin Time (High): Grade 0 (normal) to Grade 0 (normal) | 4 | 3 | 3 | 0 | 10 | 11 | 3 | 3 |
| Activated Partial Thromboplastin Time (High): Grade 0 (normal) to Grade 1 (high) | 1 | 1 | 0 | 1 | 4 | 8 | 1 | 1 |
| Activated Partial Thromboplastin Time (High): Grade 1 (high) to Grade 0 (normal) | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Activated Partial Thromboplastin Time (High): Grade 1 (high) to Grade 1(high) | 3 | 1 | 0 | 0 | 1 | 3 | 0 | 0 |
| Prothrombin Intl. Normalized Ratio (High): Grade 0 (normal) to Grade 0 (normal) | 4 | 5 | 2 | 0 | 11 | 12 | 4 | 3 |
| Prothrombin Intl. Normalized Ratio (High): Grade 0 (normal) to Grade 1 (high) | 1 | 0 | 1 | 0 | 4 | 6 | 0 | 0 |
| Prothrombin Intl. Normalized Ratio (High): Grade 0 (normal) to Grade 2 (high) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Prothrombin Intl. Normalized Ratio (High): Grade 1 (high) to Grade 0 (normal) | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Prothrombin Intl. Normalized Ratio (High): Grade 1 (high) to Grade 1 (high) | 3 | 0 | 0 | 0 | 2 | 3 | 0 | 0 |
Clinical significance of abnormalities in urinalysis was determined based on the investigator's discretion. Baseline is defined as the last assessment prior to the randomization.
| Participants | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Post-baseline Clinically Significant Urinalysis Abnormalities | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Clinical response was based on the improvement of disease-specific signs and symptoms. Responders are defined as participants meeting all the following criteria: improvement of disease-specific signs and symptoms and no new signs, symptoms or complications attributable to the initial infection; No evidence of drainage, sinus tract formation or infection-related bone instability; No requirement for subsequent antibiotics with activity against Staphylococcus to treat the initial infection after the start of study treatment; Microbiological eradication of the baseline pathogen (if post-baseline sample\[s\] are available); Imaging test at 12 weeks post-EOT showing no worsening of baseline pathology or presence of signs indicating resolution or healing of the infection. Percentages are rounded off.
| percentage of participants | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Day 8 | 87.5 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Day 28 | — | — | — | — | 0 | 77.3 | 0 | 75.0 |
| Day 42 | — | — | — | — | 0 | 4.5 | 0 | 0 |
| EOT Visit | 100 | 100 | 100 | 100 | 100 | 95.5 | 100 | 100 |
| 4 Weeks post-EOT Visit | 100 | 100 | 100 | 100 | 76.5 | 81.8 | 100 | 100 |
| 12 Weeks post-EOT Visit | 100 | 80 | 100 | 100 | 76.5 | 81.8 | 66.7 | 100 |
Collected over Up to Day 142. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Afabicin: Cohort 1 | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Part A: Afabicin: Cohort 2 | 0/5 (0%) | 1/5 (20%) | 3/5 (60%) |
| Part A: SoC: Cohort 1 | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Part A: SoC: Cohort 2 | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Part B: Afabicin: Cohort 1 | 0/18 (0%) | 3/18 (16.7%) | 10/18 (55.6%) |
| Part B: Afabicin: Cohort 2 | 1/22 (4.5%) | 4/22 (18.2%) | 18/22 (81.8%) |
| Part B: SoC: Cohort 1 | 0/4 (0%) | 1/4 (25%) | 2/4 (50%) |
| Part B: SoC: Cohort 2 | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Scar inflammationGeneral disorders | 0/8 | 0/5 | 0/3 | 0/1 | 0/18 | 0/22 | 1/4 | 0/4 |
| Hepatic enzyme increasedInvestigations | 0/8 | 1/5 | 0/3 | 0/1 | 0/18 | 0/22 | 0/4 | 0/4 |
| Acute hepatitis CInfections and infestations | 0/8 | 0/5 | 0/3 | 0/1 | 1/18 | 0/22 | 0/4 | 0/4 |
| Post procedural infectionInfections and infestations | 0/8 | 0/5 | 0/3 | 0/1 | 1/18 | 0/22 | 0/4 | 0/4 |
| Limb injuryInjury, poisoning and procedural complications | 0/8 | 0/5 | 0/3 | 0/1 | 1/18 | 0/22 | 0/4 | 0/4 |
| Arthritis bacterialInfections and infestations | 0/8 | 0/5 | 0/3 | 0/1 | 0/18 | 1/22 | 0/4 | 0/4 |
| Device related infectionInfections and infestations | 0/8 | 0/5 | 0/3 | 0/1 | 0/18 | 1/22 | 0/4 | 0/4 |
| Urinary tract infectionInfections and infestations | 0/8 | 0/5 | 0/3 | 0/1 | 0/18 | 1/22 | 0/4 | 0/4 |
| Complication associated with deviceGeneral disorders | 0/8 | 0/5 | 0/3 | 0/1 | 0/18 | 1/22 | 0/4 | 0/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/8 | 0/5 | 0/3 | 0/1 | 0/18 | 1/22 | 0/4 | 0/4 |
| Event | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 |
|---|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 1/8 | 0/5 | 0/3 | 0/1 | 3/18 | 1/22 | 0/4 | 3/4 |
| Aspartate aminotransferase increasedInvestigations | 0/8 | 0/5 | 0/3 | 0/1 | 3/18 | 1/22 | 0/4 | 2/4 |
| Hepatic enzyme increasedInvestigations | 0/8 | 2/5 | 0/3 | 0/1 | 0/18 | 0/22 | 0/4 | 0/4 |
| Blood creatine phosphokinase MB increasedInvestigations | 0/8 | 0/5 | 0/3 | 0/1 | 1/18 | 0/22 | 1/4 | 0/4 |
| SARS-CoV-2 test positiveInvestigations | 0/8 | 0/5 | 0/3 | 0/1 | 0/18 | 0/22 | 1/4 | 0/4 |
| Vitamin B12 deficiencyMetabolism and nutrition disorders | 0/8 | 0/5 | 0/3 | 0/1 | 0/18 | 0/22 | 0/4 | 1/4 |
| Scar inflammationGeneral disorders | 0/8 | 0/5 | 0/3 | 0/1 | 0/18 | 0/22 | 1/4 | 0/4 |
| TachycardiaCardiac disorders | 0/8 | 0/5 | 0/3 | 0/1 | 0/18 | 0/22 | 0/4 | 1/4 |
| HypotensionVascular disorders | 0/8 | 0/5 | 0/3 | 0/1 | 0/18 | 0/22 | 0/4 | 1/4 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 0/5 | 0/3 | 0/1 | 0/18 | 5/22 | 0/4 | 0/4 |
Safety analysis set included all randomized participants who received at least one dose of any study drug. As pre-specified in the protocol, ethnicity data was not collected in this study.
| Age, Continuous(years) | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 44.8 ± 8.12 | 55.0 ± 5.57 | 55.0 ± 1.73 | 54.0 ± NA | 43.1 ± 12.87 | 55.0 ± 16.75 | 46.8 ± 10.72 | 47.8 ± 13.05 | 49.5 ± 13.73 |
| Sex: Female, Male(Participants) | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 1 | 0 | 1 | 6 | 2 | 1 | 14 |
| Male | 6 | 4 | 2 | 1 | 17 | 16 | 2 | 3 | 51 |
| Race (NIH/OMB)(Participants) | Part A: Afabicin: Cohort 1 | Part A: Afabicin: Cohort 2 | Part A: SoC: Cohort 1 | Part A: SoC: Cohort 2 | Part B: Afabicin: Cohort 1 | Part B: Afabicin: Cohort 2 | Part B: SoC: Cohort 1 | Part B: SoC: Cohort 2 | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 4 |
| White | 8 | 5 | 3 | 1 | 18 | 19 | 4 | 2 | 60 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Apr 2025, 74 months.
Results were first posted in Sep 2026, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Afabicin